biostudies-literatureLoRusso PMStand Up To CancerNCATS NIH HHSGateway for Cancer ResearchNCI NIH HHSe0248097https://www.ebi.ac.uk/biostudies/studies/S-EPMC8026051biostudies-literatureUnknown16(4)Although combination BRAF and MEK inhibitors are highly effective for the 40-50% of cutaneous metastatic melanomas harboring BRAFV600 mutations, targeted agents have been ineffective for BRAFV600wild-type (wt) metastatic melanomas. The SU2C Genomics-Enabled Medicine for Melanoma Trial utilized a Simon two-stage optimal design to assess whether comprehensive genomic profiling improves selection of molecular-based therapies for BRAFV600wt metastatic melanoma patients who had progressed on standard-of-care therapy, which may include immunotherapy. Of the response-evaluable patients, binimetinib was selected for 20 patients randomized to the genomics-enabled arm, and nine were treated on the alternate treatment arm. Response rates for 27 patients treated with targeted recommendations included PloS oneIdentifying treatment options for BRAFV600 wild-type metastatic melanoma: A SU2C/MRA genomics-enabled clinical trial.PMC8026051G-12-500P30 CA008748UL1 TR001863SU2C-AACR-DT0612Sekulic AHalperin RLao CByron SADeVeaux MKiefer JACalvert VSIzatt TNasser SKeats JSchork NEder JPSchmidt JSekar SManica BCraig DWHendricks WPDBryce AHCowey CLMarkovic SNFecher LAFox LVogelzang NJJoseph RWDurecki DPetricoin EFPerlmutter JGorman MLegendre CEnriquez DLoRusso PMZelterman DZismann VAldrich JTrent JMLiang WSPilat MJNaveed FSivaprakasam KBasu GDCarpten JWeise ASosman JABoerner SAAdkins JSolit DBTassone EfalseIdentifying treatment options for BRAFV600 wild-type metastatic melanoma: A SU2C/MRA genomics-enabled clinical trial.Although combination BRAF and MEK inhibitors are highly effective for the 40-50% of cutaneous metastatic melanomas harboring BRAFV600 mutations, targeted agents have been ineffective for BRAFV600wild-type (wt) metastatic melanomas. The SU2C Genomics-Enabled Medicine for Melanoma Trial utilized a Simon two-stage optimal design to assess whether comprehensive genomic profiling improves selection of molecular-based therapies for BRAFV600wt metastatic melanoma patients who had progressed on standard-of-care therapy, which may include immunotherapy. Of the response-evaluable patients, binimetinib was selected for 20 patients randomized to the genomics-enabled arm, and nine were treated on the alternate treatment arm. Response rates for 27 patients treated with targeted recommendations included 2021-01-01T00:00:00Z20212026-04-29T00:20:27.921Z2022-02-09T15:59:30.727ZS-EPMC80260513382661410.1371/journal.pone.0248097